Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract
U Harmenberg, B Wahren, KL Wiechel - Cancer Research, 1988 - AACR
U Harmenberg, B Wahren, KL Wiechel
Cancer Research, 1988•AACRSera from patients with diseases in the pancreas, gallbladder, and bile duct were analyzed
for the tumor markers CA 19-9, CA-50, and carcinoembryonic antigen. In particular CA 19-9
and CA-50 appear to be valuable in differentiating malignant from benign disease in these
organs. Our sample of 72 patients with pancreatic cancer also indicates that CA 19–9 and
CA-50 complement each other in 21% of the cases. They are also shown to be reliable for
monitoring disease: following radical surgery for pancreatic cancer low levels of CA 19-9 …
for the tumor markers CA 19-9, CA-50, and carcinoembryonic antigen. In particular CA 19-9
and CA-50 appear to be valuable in differentiating malignant from benign disease in these
organs. Our sample of 72 patients with pancreatic cancer also indicates that CA 19–9 and
CA-50 complement each other in 21% of the cases. They are also shown to be reliable for
monitoring disease: following radical surgery for pancreatic cancer low levels of CA 19-9 …
Abstract
Sera from patients with diseases in the pancreas, gallbladder, and bile duct were analyzed for the tumor markers CA 19-9, CA-50, and carcinoembryonic antigen. In particular CA 19-9 and CA-50 appear to be valuable in differentiating malignant from benign disease in these organs. Our sample of 72 patients with pancreatic cancer also indicates that CA 19–9 and CA-50 complement each other in 21% of the cases. They are also shown to be reliable for monitoring disease: following radical surgery for pancreatic cancer low levels of CA 19-9 and CA-50 were noted, while progressive rises of these tumor markers were related to disease progression.
AACR